Lipoprotein(a) has been strongly suggested to be a risk factor for atherosclerosis. However, its metabolism and/or regulation by drug treatment still remain unknown.Wetherefore studied the effects of glucocorticoid therapy on serum lipoprotein(a) in rheumatic diseases. Although the glucocorticoid treatment increased the total serum cholesterol, high-density lipoprotein cholesterol and apolipoprotein B concentrations, it reduced the serum lipoprotein(a) concentration (mean, 40%) in a dose-dependent manner in 9 patients with rheumatic diseases without nephrotic syndrome. Similar results were observed in 2 patients who did have nephrotic syndrome. It is assumed that the increase of total cholesterol and apolipoprotein B in serum levels are atherogenic, whereas the increase of high-density lipoprotein cholesterol and the decrease of lipoprotein(a) are protective for atherosclerosis. The clinical outcome of the concomitant results in lipid metabolism in the development of atherosclerosis remains to be studied. (Internal Medicine 32: 382-386, 1993) 
Introduction
Atherosclerosis in patients with rheumatic diseases under glucocorticoid therapy entails important clinical problems ( 1 , 2) . However, the pathogenesis of atherosclerosis in these patients is not well understood. Since glucocorticoids had been reported to enhance risk factors of coronary artery atherosclerosis, such as hypertension, impaired glucose tolerance, and hyperlipidemia, glucocorticoid therapy is assumed to be an accelerating factor of atherosclerosis (3) . However, it is generally observed that glucocorticoid therapy increases total serum, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol levels, suggesting a concomitant increase in atherogenic and protective lipoproteins with the development of atherosclerosis (4) . Thus, the effects of hyperlipidemia due to glucocorticoid therapy on the clinical outcome have not yet been elucidated (4) . Recently, lipoprotein(a) [Lp(a)] has been strongly suggested as an independent risk factor for atherosclerotic vascular diseases such as coronary artery disease (5, 6) and cerebral infarction (6) . However, the effects of glucocorticoids on Lp(a) concentration have not yet been studied. In this study, we measured serum Lp(a) concentrations in patients with rheumatic diseases before and after glucocorticoid therapy. Other lipid and apolipoprotein levels in the same samples were measured as well.
Patients and Methods

Patients
Eleven inpatients with rheumatic diseases [8 with systemic lupus erythematosus (SLE), 2 with adult onset Still's disease, and 1 with rheumatoid arthritis (RA) with vasculitis] were studied. The patients with SLEand RAfulfilled the set of criteria for SLE and RAof the American Rheumatism Association. No patients had conditions associated with hepatic disorders, renal failure, diabetes mellitus, or pregnancy. Nine patients (Cases 1 to 9) did not have nephrotic syndrome, while 2 (Cases 10 and ll) with SLE had nephrotic syndrome due to lupus nephritis. Four patients with SLErequired glucocorticoid therapy for the first time, and the others received an increased dosage (15-50 mg/day) of prednisolone compared to the respective maintenance dosages (4-1 0 mg/day). The clinical data of each patient are given in Tables 1 and 2 . The patients received no other drugs except nifedipine (2 patients), furosemide (1 patient), methotrexate (1 patient) and aluminium hydroxide pulse therapy (5 mg/week). The clinical course in this case is shown in Fig. 1 . Case 10 was a 25-year-old female with SLEwith nephrotic syndrome whowas admitted to our hospital and treated with 50 mg of prednisolone daily. After 2 months, her serum albumin concentration gradually improved from 1.6 g/dl to 2.5 g/dl. The clinical course in this case is shown in Fig. 2 .
Assay procedures
Blood was collected after an overnight fast. Aliquots of serum were frozen and stored at -70°C. Serum Lp(a) concentration was determined by an enzyme-linked immunosorbent assay (TintElize Lp(a), Biopool AB, Umea, Sweden). Estimated cross-reactivity of plasminogen to this assay procedure was 0.0034%. Total serum cholesterol and triglyceride concentrations were measured by enzymatic methods using an autoanalyzer (Hitachi 736-40, Tokyo, Japan). HDLcholesterol was determined after isolation by a precipitation method (7) . Apolipoprotein B in the serum was determined by turbidimetric immunoassayusing an autoanalyzer (8). Wilcoxon's signed rank test wasused for statistical analysis.
Results
The serum Lp(a) concentrations in Cases 1 and 10 were followed for several months ( Figs. 1 and 2 ). Those levels were decreased immediately after the administration of the initial therapeutic doses ofprednisolone, but they recovered gradually to almost the same levels after the tapering of prednisolone administration. In Case 1 , the Lp(a) levels decreased again after renewed treatment with prednisolone at a high dose. In contrast, serum apolipoprotein B , total and HDLcholesterol concentrations in these patients were increased consistently after glucocorticoid therapy. The lipid and lipoprotein parameters before and 14-20 days after glucocorticoid therapy in 9 patients with rheumatic diseases without nephrotic syndromeare shownin Table 1 . The glucocorticoid caused a significant reduction in serum Lp(a) concentration (mean, 40%). In contrast, serum apolipoprotein B (34%), and total (50%) and HDL cholesterol (64%) concentrations were increased significantly after glucocorticoid therapy. The mean value of serum triglyceride levels did not change.
The lipid and lipoprotein parameters in 2 patients with SLE complicated with nephrotic syndrome are shown in Table 2 . The results showed almost the same tendency as for those in 9 patients without nephrotic syndrome.
The changes of serum Lp(a) concentrations in all the patients after glucocorticoid therapy are shown in Fig. 3 . The Lp(a) levels had decreased in them all, including those with nephrotic tration after glucocorticoid therapy (between 14 and 20 days) was observed in the 9 patients without nephrotic syndrome (Fig.   4 ).
The erythrocyte sedimentation rate or the serum C-reactive protein concentration did not correlate with serum Lp(a) concentration in these patients (data not shown). The percent decrease or the decreased value of Lp(a) did not correlate with the increased value of HDLcholesterol after glucocorticoid therapy (data not shown).
Discussion
Serum Lp(a) levels are highly hereditable, but not associated with sex, age, plasma lipids, or other lipoproteins (9) . However, the present study showed that serum Lp(a) levels were decreased after glucocorticoid therapy in patients with rheumatic diseases whodid not have pathological conditions associated with hepatic disorders, renal failure, diabetus mellitus, pregnancy, or nephrotic syndrome, all of which are reported to be associated with elevated Lp(a) levels (9, 10) . In addition, there was a significant correlation between the increased dosage of prednisolone and the changes in Lp(a) concentration. These results suggest that glucocorticoid therapy in itself decreases the serum Lp(a) concentration in rheumatic diseases. Two patients with SLE (Cases 10 and ll) had nephrotic syndrome. The reduction of Lp(a) levels after glucocorticoid therapy in these patients maybe attributed to the improvement ofnephrotic syndrome rather than the effect of the glucocorticoid. However, in Case 10, the serum albumin concentration increased gradually over 2 months. If her serum Lp(a) concentration was regulated only by the severity of the nephrotic syndrome, the decreased level should have been maintained throughout the period of clinical improvement. On the contrary, her serum Lp(a) level had decreased first, and then it had increased with the reduction in dosage of the prednisolone. Thus, her serum Lp(a) level might have been regulated by the amount of prednisolone rather than by the condition of the nephrotic syndrome.
Recently, Dahlqvist et al (1 1) reported that the mean plasma concentration of Lp(a) in patients with RAwas high compared to that of normal controls. Theyalso reported that there was no significant difference between those whowere treated and those not treated with glucocorticoids. However, they did not show the detailed data ofglucocorticoid administration and also the data of the changes of Lp(a) after glucocorticoid therapy in the same patients. Our results show that glucocorticoid therapy obviously decreases serum Lp(a) concentration in rheumatic diseases.
Lp(a) is not affected by most cholesterol-lowering drugs (9, 12) , however, stanazolol (13) , neomycin and niacin in combination (14) , nicotinic acid (15) , N-acetylcysteine (16) , and diethylstilbesterol ( 17) are reported to reduce serum or plasma Lp(a) levels. Stanazolol decreases both Lp(a) and HDLcholesterol levels, but does not change the apolipoprotein B level in plasma (13) . Nicotinic acid treatments combined with and without neomycin decrease serum Lp(a) and LDLcholesterol concentrations in patients with hyperlipidemia (14, 15) . While N-acetylcysteine, a disulphide bond-reducing agent, reduces the serum levels of Lp(a), it was shown to increase the LDL cholesterol level in 2 patients with hyperlipidemia (16) . A synthetic estrogen, diethylstilbesterol, decreases both the Lp(a) and LDLcholesterol levels, but it increased the HDLcholesterol level in a male patient with familial hypercholesterolemia ( 1 7). Thus, the characteristics of various lipid concentrations in this study are similar to those of N-acetylcysteine, but not to those of other Lp(a)-reducing drugs. Lp(a) is a complex of LDLand apo(a) linked by disulphide bonds. It is assumed that N-acetylcysteine reduces Lp(a) levels by dissociating apo(a) from Lp(a) and/or by inhibiting Lp(a) formation (16) . Since no glucocorticoid has been reported to be a disulphide bond-reducing agent, the mechanismsof the reduction of Lp(a) level by glucocorticoid therapy still remain obscure.
The HDL cholesterol level, a preventive factor for atherosclerosis, was increased dramatically 14-20 days after the start of glucocorticoid therapy in the present study. These data are consistent with those on pediatric patients with SLE reported by Ilowite et al (18) . They implied that such changes in HDLcholesterol with glucocorticoid administration might cause a decrease in the risk of atherosclerosis. Theeffects of glucocorticoid administration in healthy volunteers and patients with various disorders requiring glucocorticoid therapy were summarized by Henkin et al (4) . The increase in the HDL cholesterol level after glucocorticoid therapy is generally more prominent than that in total or LDLcholesterol. The results in the present study show the same trend as those in the previous reports.
Wefound that the serum Lp(a) concentration, possibly atherogenic lipoprotein, was not increased rather it was decreased by glucocorticoid therapy. The possible mechanism of this finding may be a reduction in Lp(a) production or an increase in Lp(a) clearance from serum. It might suggest that as far as Lp(a) and other lipoprotein metabolism is concerned, glucocorticoid therapy can reduce the risk of atherosclerosis in rheumatic diseases if glucocorticoids reduce the production of Lp(a) or if they increase the total body clearance of Lp(a). In contrast, ifglucocorticoid therapy increases the clearance of the Lp(a) from serum into the arterial wall, it might be that the risk of atherosclerosis is increased. Further examination to elucidate the mechanismsof serum Lp(a) reduction after glucocorticoid therapy will be necessary.
